Skip to content

13F-HR filed by Stonepine Capital Management, LLC

Stonepine Capital Management, LLC filed this 13F-HR for the quarter ended 2019-03-31, filed 2019-05-14, with 30 holding rows worth $173,855,000.

Accession
0001567619-19-010831
Filed
2019-05-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2019

A holdings report, 30 entries on the cover page, a total value of $173,855,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $173,855,000 with VALUE read as thousands by filing date, 13F file number 028-17175. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
VANDA PHARMACEUTICALS INC921659108COM1,260,288$23,189,000thousands by filing date
AMARIN CORP PLC023111206SPONS ADR NEW946,379$19,647,000thousands by filing date
LIGAND PHARMACEUTICALS INC53220K504COM NEW150,000$18,857,000thousands by filing date
NEOS THERAPEUTICS INC64052L106COM4,511,504$11,775,000thousands by filing date
APOLLO ENDOSURGERY INC03767D108COM2,580,518$9,651,000thousands by filing date
BIODELIVERY SCIENCES INTL IN09060J106COM1,539,437$8,159,000thousands by filing date
HTG MOLECULAR DIAGNOSTICS IN40434H104COM2,835,786$7,089,000thousands by filing date
ADAMAS PHARMACEUTICALS INC00548A106COM984,329$6,999,000thousands by filing date
CUMBERLAND PHARMACEUTICALS I230770109COM1,201,975$6,983,000thousands by filing date
ALIMERA SCIENCES INC016259103COM6,483,610$6,873,000thousands by filing date
AEGERION PHARMACEUTICALS INC00767EAB8NOTE 2.000 8/19,000,000$6,032,000thousands by filing date
ENANTA PHARMACEUTICALS INC29251M106COM60,840$5,811,000thousands by filing date
OPHTHOTECH CORP683745103COM4,074,944$5,746,000thousands by filing date
CTI BIOPHARMA CORP12648L601COM4,000,000$3,881,000thousands by filing date
OPIANT PHARMACEUTICALS INC683750103COM294,894$3,869,000thousands by filing date
APTEVO THERAPEUTICS INC03835L108COM3,894,219$3,505,000thousands by filing date
VIVEVE MED INC92852W204COM NEW3,403,402$3,199,000thousands by filing date
XOMA ROYALTY CORPORATION98419J206COMMON STOCK227,430$2,816,000thousands by filing date
FOAMIX PHARMACEUTICALS LTDM46135105SHS730,004$2,738,000thousands by filing date
EMERGENT BIOSOLUTIONS INC29089Q105COM46,800$2,364,000thousands by filing date
OXFORD IMMUNOTEC GLOBAL PLCG6855A103ORD SHS127,224$2,192,000thousands by filing date
MATINAS BIOPHARMA HLDGS INC576810105COM2,008,006$2,189,000thousands by filing date
AFFIMED N VN01045108COM505,736$2,124,000thousands by filing date
CHIASMA INC16706W102COM300,000$1,560,000thousands by filing date
VERASTEM INC92337C104COM500,000$1,480,000thousands by filing date
INTERPACE DIAGNOSTICS GROUP46062X204COM NEW1,434,030$1,147,000thousands by filing date
DIAMEDICA THERAPEUTICS INC25253X207COMMON STOCK250,000$1,135,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock98,860$1,004,000thousands by filing date
STRONGBRIDGE BIOPHARMA PLCG85347105SHS USD187,074$932,000thousands by filing date
COLLEGIUM PHARMACEUTICAL INC19459J104COM60,045$909,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001567619-19-010831this filing2019-05-14acceptance time not in the bulk data set